Biotech


  • A man dressed in a suit looks at the camera in this headshot.
    Image attribution tooltip
    Permission granted by FogPharma
    Image attribution tooltip

    FogPharma pulls in $145M to support cancer drug research

    The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.

    By March 1, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    Gritstone to lay off 40% of workforce after costly study delay

    The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.

    By March 1, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?

    By BioPharma Dive staff
  • Three business men stand on a city street for a photo
    Image attribution tooltip
    Courtesy of Cure Ventures
    Image attribution tooltip

    Cure Ventures backs a cell therapy startup targeting Parkinson’s

    The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.

    By Feb. 29, 2024
  • Several California poppies are seen in bloom.
    Image attribution tooltip
    GomezDavid via Getty Images
    Image attribution tooltip

    With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease

    Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding. 

    By Feb. 29, 2024
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Abingworth invests in Trodelvy development in deal with Gilead

    One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.

    By Kristin Jensen • Feb. 29, 2024
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Women’s health company Obseva to wind down, lay off staff

    The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.

    By Feb. 28, 2024
  • Viatris pays $350M to gain two drugs from Idorsia

    The deal gives Viatris access to a treatment for heart attacks as well as a drug for lupus, both of which are currently in Phase 3 testing.

    By Kristin Jensen • Feb. 28, 2024
  • A photo of a Gingko Bioworks office
    Image attribution tooltip
    Courtesy of Ginkgo Bioworks
    Image attribution tooltip

    Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup

    The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes for making genetic medicines.

    By Feb. 28, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a Moderna co-founder change the CRO game?

    Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.

    By Michael Gibney • Feb. 28, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Viking data suggest obesity drug could rival Zepbound, Wegovy

    The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

    By Feb. 27, 2024
  • A concept illustration of malignant cells, colored purple and red
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Janux shares triple on early cancer immunotherapy data

    Analysts viewed results for one of Janux’s drug, a T cell engager aimed at metastatic prostate cancer, as potentially best-in-class in a field that’s crowded with competitors.

    By Feb. 27, 2024
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    Denali, fresh off study setback, gets $500M lift

    The infusion from unnamed private investors will bolster the company’s balance sheet days after a Sanofi-partnered ALS drug stumbled in a clinical trial.

    By Feb. 27, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Feb. 23, 2024
  • A headshot of Chris Varma, CEO of Frontier Medicines.
    Image attribution tooltip
    Permission granted by Frontier Medicines
    Image attribution tooltip

    Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

    The startup’s Series C round will support a clinical-stage drug the company thinks could address the shortcomings of other KRAS-targeting medicines.

    By Feb. 22, 2024
  • President Joe Biden signs a bill in the Oval Office while First Lady Jill Biden and others look on.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biden administration pledges $100M toward women’s health research

    The commitment is part of an initiative led by First Lady Jill Biden to change how research into diseases that mostly affect women gets funded in the U.S.

    By Feb. 22, 2024
  • View of Moderna headquarters
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’

    The biotech is counting on an experimental RSV vaccine, currently under review by the FDA, to drive sales in the future.

    By Feb. 22, 2024
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    Novavax agrees to pay Gavi in settlement over COVID vaccine contract

    Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.

    By Kristin Jensen • Feb. 22, 2024
  • An array of multi-colored pills are shown together in this stock image.
    Image attribution tooltip
    FotografiaBascia via Getty Images
    Image attribution tooltip

    ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund

    The $260 million fund will be used to back startups working on new drugmaking approaches like protein degraders and RNA therapies.

    By Feb. 22, 2024
  • Empty boardroom meeting space in office
    Image attribution tooltip
    jamenpercy via Getty Images
    Image attribution tooltip

    Vir, in midst of restructuring, loses its chief medical officer

    The departure of Phil Pang, who played a key role in developing Vir’s COVID-19 antibody, comes amid a broader company restructuring.

    By Feb. 21, 2024
  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Bavarian Nordic terminates cancer vaccine work

    The Danish company scrapped a vaccine in Phase 1 testing and will exit oncology altogether, focusing instead on infectious disease research.

    By Feb. 21, 2024
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    United Therapeutics, in unusual step, sues FDA over rival’s drug application

    The biotech alleges the agency is letting rival Liquidia sidestep the rules by accepting an amendment to an application that’s involved in a patent dispute.

    By Kristin Jensen • Feb. 21, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the new kind of cell therapy that just won FDA approval

    One expert views Amtagvi’s approval as a catalyst for further investment in TIL therapies, akin to how Kymriah’s 2017 clearance buoyed CAR-T treatment.

    By Kelly Bilodeau • Feb. 21, 2024
  • Recession arrow, Graph showing business decline on led screen
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA puts hold on Rapt trials of drug for eczema, asthma

    Rapt reported one case of liver failure in a study participant who received the biotech’s drug, which is seen by analysts as a possible competitor to Dupixent.

    By Feb. 20, 2024
  • mirror laptop image showing image of client portal with blue background
    Image attribution tooltip
    Permission granted by ClinicalMind
    Image attribution tooltip
    Sponsored by ClinicalMind

    Here are 7 practical ways asynchronous advisory programs can make an impact in 2024

    Can asynchronous advisory programs can add distinct value to your strategic mix? Yes! Here's how.

    Feb. 20, 2024
  • A 3D visualization of neurons and neural network with signals.
    Image attribution tooltip
    Evgenii Kovalev via Getty Images
    Image attribution tooltip
    ALS drug development

    ALS drug from Denali, Sanofi falls short in mid-stage study

    The disclosure the experimental therapy missed its trial goal comes after Sanofi had earmarked the drug for advancement into Phase 3.

    By Feb. 16, 2024